Therapeutics targeting a novel pathway to treat acute inflammation and prevent tissue damage.
  • About
  • Science
  • Research and Development Programs
  • News
  • Contact

DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab™, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases.


DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding
Press Release


DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody
Press Release